LOXO-305 (Pirtobrutinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LOXO-305 (Pirtobrutinib), covering 2025-03-07 to 2025-03-07. Get the full timeline:
Most recent: Clinical Trial Update: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]